Chlorogenic Acid Inhibits Progressive Pulmonary Fibrosis in a Diabetic Rat Model.

IF 1.6 Q2 MEDICINE, GENERAL & INTERNAL

Iranian Journal of Medical Sciences Pub Date : 2024-02-01 DOI:10.30476/IJMS.2023.96535.2868

Sagita Mega Sekar Kencana, Nur Arfian, Ratih Yuniartha, Ramadhea Laila Afifa An-Nur Willya Saputri, Fauziyatul Munawaroh, Dwi Cahyani Ratna Sari

{"title":"Chlorogenic Acid Inhibits Progressive Pulmonary Fibrosis in a Diabetic Rat Model.","authors":"Sagita Mega Sekar Kencana, Nur Arfian, Ratih Yuniartha, Ramadhea Laila Afifa An-Nur Willya Saputri, Fauziyatul Munawaroh, Dwi Cahyani Ratna Sari","doi":"10.30476/IJMS.2023.96535.2868","DOIUrl":null,"url":null,"abstract":"Background: Chlorogenic acid (CGA) is known to have antifibrotic and hypoglycemic effects and may play a role in preventing diabetes-induced pulmonary fibrosis. This study aimed to determine the effect and optimum dose of CGA on diabetes-induced pulmonary fibrosis.Methods: Thirty Wistar rats (two-month-old, 150-200 grams) were randomly divided into six groups, namely control, six weeks diabetes mellitus (DM1), eight weeks DM (DM2), and three DM2 groups (CGA1, CGA2, and CGA3) who received CGA doses of 12.5, 25, and 50 mg/Kg BW, respectively. After six weeks, CGA was administered intraperitoneally for 14 consecutive days. Lung tissues were taken for TGF-β1, CTGF, SMAD7, Collagen-1, and α-SMA mRNA expression analysis and paraffin embedding. Data were analyzed using one-way ANOVA and the Kruskal-Wallis test. P<0.05 was considered statistically significant.Results: TGF-β1 expression in the CGA1 group (1.01±0.10) was lower than the DM1 (1.33±0.25, P=0.05) and DM2 (1.33±0.20, P=0.021) groups. α-SMA expression in the CGA1 group (median 0.60, IQR: 0.34-0.64) was lower than the DM1 (median 0.44, IQR: 0.42-0.80) and DM2 (median 0.76, IQR: 0.66-1.10) groups. Collagen-1 expression in the CGA1 group (0.75±0.13) was lower than the DM1 (P=0.24) and DM2 (P=0.26) groups, but not statistically significant. CTGF expression in CGA groups was lower than the DM groups (P=0.088), but not statistically significant. There was an increase in SMAD7 expression in CGA groups (P=0.286). Histological analysis showed fibrosis improvement in the CGA1 group compared to the DM groups.Conclusion: CGA (12.5 mg/Kg BW) inhibited the expression of profibrotic factors and increased antifibrotic factors in DM-induced rats.","PeriodicalId":14510,"journal":{"name":"Iranian Journal of Medical Sciences","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10862105/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30476/IJMS.2023.96535.2868","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Chlorogenic acid (CGA) is known to have antifibrotic and hypoglycemic effects and may play a role in preventing diabetes-induced pulmonary fibrosis. This study aimed to determine the effect and optimum dose of CGA on diabetes-induced pulmonary fibrosis.

Methods: Thirty Wistar rats (two-month-old, 150-200 grams) were randomly divided into six groups, namely control, six weeks diabetes mellitus (DM1), eight weeks DM (DM2), and three DM2 groups (CGA1, CGA2, and CGA3) who received CGA doses of 12.5, 25, and 50 mg/Kg BW, respectively. After six weeks, CGA was administered intraperitoneally for 14 consecutive days. Lung tissues were taken for TGF-β1, CTGF, SMAD7, Collagen-1, and α-SMA mRNA expression analysis and paraffin embedding. Data were analyzed using one-way ANOVA and the Kruskal-Wallis test. P<0.05 was considered statistically significant.

Results: TGF-β1 expression in the CGA1 group (1.01±0.10) was lower than the DM1 (1.33±0.25, P=0.05) and DM2 (1.33±0.20, P=0.021) groups. α-SMA expression in the CGA1 group (median 0.60, IQR: 0.34-0.64) was lower than the DM1 (median 0.44, IQR: 0.42-0.80) and DM2 (median 0.76, IQR: 0.66-1.10) groups. Collagen-1 expression in the CGA1 group (0.75±0.13) was lower than the DM1 (P=0.24) and DM2 (P=0.26) groups, but not statistically significant. CTGF expression in CGA groups was lower than the DM groups (P=0.088), but not statistically significant. There was an increase in SMAD7 expression in CGA groups (P=0.286). Histological analysis showed fibrosis improvement in the CGA1 group compared to the DM groups.

Conclusion: CGA (12.5 mg/Kg BW) inhibited the expression of profibrotic factors and increased antifibrotic factors in DM-induced rats.

查看原文本刊更多论文

绿原酸抑制糖尿病大鼠模型中的进行性肺纤维化

背景：绿原酸（CGA）具有抗纤维化和降血糖作用，可能在预防糖尿病诱发的肺纤维化中发挥作用。本研究旨在确定 CGA 对糖尿病诱导的肺纤维化的影响和最佳剂量：将 30 只 Wistar 大鼠（两个月大，体重 150-200 克）随机分为六组，即对照组、糖尿病六周组（DM1）、糖尿病八周组（DM2）和三个 DM2 组（CGA1、CGA2 和 CGA3），各组接受的 CGA 剂量分别为 12.5、25 和 50 毫克/千克体重。六周后，连续 14 天腹腔注射 CGA。取肺组织进行 TGF-β1、CTGF、SMAD7、Collagen-1 和 α-SMA mRNA 表达分析和石蜡包埋。数据分析采用单因素方差分析和 Kruskal-Wallis 检验。结果CGA1组（1.01±0.10）的TGF-β1表达量低于DM1组（1.33±0.25，P=0.05）和DM2组（1.33±0.20，P=0.021）。CGA1组的α-SMA表达量（中位数0.60，IQR：0.34-0.64）低于DM1组（中位数0.44，IQR：0.42-0.80）和DM2组（中位数0.76，IQR：0.66-1.10）。CGA1组的胶原蛋白-1表达量（0.75±0.13）低于DM1组（P=0.24）和DM2组（P=0.26），但无统计学意义。CGA组的CTGF表达低于DM组（P=0.088），但无统计学意义。CGA组中SMAD7的表达有所增加（P=0.286）。组织学分析表明，与 DM 组相比，CGA1 组的纤维化有所改善：结论：CGA（12.5 毫克/千克体重）可抑制 DM 诱导的大鼠促纤维化因子的表达，并增加抗纤维化因子。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Iranian Journal of Medical Sciences MEDICINE, GENERAL & INTERNAL-

CiteScore

3.20

自引率

0.00%

发文量

审稿时长

12 weeks

期刊介绍： The Iranian Journal of Medical Sciences (IJMS) is an international quarterly biomedical publication, which is sponsored by Shiraz University of Medical Sciences. The IJMS intends to provide a scientific medium of communication for researchers throughout the globe. The journal welcomes original clinical articles as well as clinically oriented basic science research experiences on prevalent diseases in the region and analysis of various regional problems.